Sequent Scientific's Q1 FY 2025-26 Quarterly Results

Result Summary

• Sequent Scientific Ltd reported a 21.9% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 13.3%.
• Its expenses for the quarter were up by 17.0% QoQ and 9.9% YoY.
• The net profit increased 1283.5% QoQ and increased 93.9% YoY.
• The earnings per share (EPS) of Sequent Scientific Ltd stood at 0.6 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Sequent Scientific Ltd is a company operating primarily in the pharmaceutical industry, focusing on veterinary pharmaceuticals. This specialization involves the production and supply of animal health products, which are essential for ensuring the well-being of livestock and pets. The company is known for its manufacturing and distribution capabilities, serving various markets globally. As of the latest data available, there are no specific details about recent major developments or strategic changes within the company. However, the industry typically faces influences from regulatory changes, advancements in healthcare technology, and shifts in market demand for veterinary products.

Revenue

In the first quarter of fiscal year 2026 (Q1FY26), Sequent Scientific Ltd reported a total income of ₹445.29 crores. This represents a significant increase of 21.9% quarter-over-quarter (QoQ) from ₹365.20 crores in the fourth quarter of fiscal year 2025 (Q4FY25). Year-over-year (YoY), there is a 13.3% increase from ₹392.89 crores reported in the first quarter of fiscal year 2025 (Q1FY25). This upward trajectory in revenue can be attributed to various factors that are not detailed in the available financial data. The increase in total income highlights a period of growth for the company during this quarter.

Profitability

The profitability of Sequent Scientific Ltd showed notable improvements in Q1FY26. The profit before tax was ₹25.52 crores, marking a substantial QoQ increase of 866.7% from ₹2.64 crores in Q4FY25, and a YoY increase of 112.7% from ₹12.00 crores in Q1FY25. After accounting for taxes, the profit after tax stood at ₹17.57 crores, highlighting an impressive QoQ growth of 1283.5% from ₹1.27 crores in the previous quarter and a YoY growth of 93.9% from ₹9.06 crores in the same quarter last year. Earnings per share (EPS) also doubled YoY, from ₹0.30 to ₹0.60. These figures illustrate a strong performance in profitability metrics for the given period.

Operating Metrics

Total expenses for Sequent Scientific Ltd in Q1FY26 amounted to ₹418.52 crores, increasing by 17.0% QoQ from ₹357.85 crores in Q4FY25 and by 9.9% YoY from ₹380.89 crores in Q1FY25. The significant rise in expenses, while substantial, was overshadowed by the increase in total income, resulting in improved profit margins. The tax expense also saw a rise, recorded at ₹7.95 crores, which is a 484.6% QoQ increase from ₹1.36 crores and a 170.4% YoY increase from ₹2.94 crores. These operating metrics reflect the company's financial management and cost structure during the quarter.